Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma Group has released its 2025 Corporate Governance Statement, emphasizing its adherence to the ASX Corporate Governance Principles and Recommendations. The Board of Directors is committed to guiding the company with a focus on shareholder interests, risk management, and ethical conduct. The statement highlights the company’s comprehensive governance policies, including a Business Code of Conduct and various committee charters, which are available on its website. This release underscores Mayne Pharma’s dedication to updating its governance practices in line with evolving standards, potentially strengthening its industry position and stakeholder trust.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a company listed on the Australian Securities Exchange (ASX:MYX) that operates in the pharmaceutical industry. The company is focused on developing and manufacturing branded and generic pharmaceutical products, with a commitment to maintaining high standards of ethics and integrity.
Average Trading Volume: 287,045
Technical Sentiment Signal: Buy
Current Market Cap: A$475.3M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.